• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acids

Introduction to 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid (CAS No. 35195-86-9)

3-(4-methyl-1,3-thiazol-2-yl)benzoic acid, identified by the Chemical Abstracts Service registry number 35195-86-9, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry due to its unique structural properties and potential biological activities. This compound belongs to the benzoic acid derivatives class, incorporating a thiazole moiety at the 3-position, which is a well-documented scaffold in drug discovery. The presence of the 4-methyl substituent further modulates its electronic and steric characteristics, making it a promising candidate for further exploration.

The structural framework of 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid combines the aromatic stability of benzoic acid with the bioisosteric properties of thiazole rings. Thiazole derivatives are widely recognized for their role in various biological processes, including antimicrobial, anti-inflammatory, and anticancer activities. The benzoic acid moiety is also a key pharmacophore in many drugs, contributing to solubility, metabolic stability, and binding affinity to biological targets. The synergistic effect of these two components makes 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid an intriguing molecule for medicinal chemists.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding interactions of 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid with various biological targets. Studies suggest that this compound may exhibit inhibitory effects on enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are pivotal in inflammatory pathways. Additionally, the thiazole ring has been shown to interact with DNA-binding proteins, potentially leading to applications in oncology. These findings underscore the compound's potential as a lead structure for developing novel therapeutic agents.

In vitro studies have demonstrated that 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid possesses antioxidant properties, which are attributed to its ability to scavenge reactive oxygen species (ROS). This property is particularly relevant in the context of oxidative stress-related diseases, such as neurodegenerative disorders and cardiovascular conditions. The compound's ability to modulate redox signaling pathways may offer a new therapeutic strategy for these conditions. Furthermore, preliminary pharmacokinetic studies indicate that 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid exhibits favorable absorption and distribution profiles when administered orally.

The synthesis of 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid involves multi-step organic reactions that require precise control over reaction conditions. Key synthetic steps include the condensation of 4-methylthiazole with appropriately substituted benzoyl halides or carboxylic acids under basic conditions. Advances in synthetic methodologies have enabled more efficient and scalable production processes for this compound. For instance, catalytic hydrogenation techniques have been employed to introduce functional groups with high selectivity and yield.

Industrial applications of 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid are currently being explored in collaboration with pharmaceutical companies. These collaborations aim to evaluate its efficacy in preclinical models and assess its potential for further development into clinical candidates. The compound's structural features make it amenable to derivatization, allowing researchers to fine-tune its pharmacological profile. For example, modifications at the carboxylic acid group can enhance solubility or improve binding affinity depending on the desired therapeutic outcome.

The role of computational tools in optimizing drug candidates like 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid cannot be overstated. Machine learning algorithms have been trained on large datasets of bioactive compounds to predict their biological activity and toxicity profiles. These predictions help guide experimental design by prioritizing promising candidates for further testing. Additionally, virtual screening techniques have been used to identify potential off-target effects that could impact safety and efficacy.

Future research directions for 3-(4-methyl-1,3-thiazol-2-yl)benzoic acid include investigating its mechanism of action in detail and exploring its potential as an adjuvant therapy in combination with existing treatments. The compound's ability to modulate multiple biological pathways suggests that it may have broad therapeutic applications across various disease states. As our understanding of molecular interactions continues to evolve, so too will our ability to harness natural products like this one for human health.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)